Listing 16.2.1-4.2-1: Listing of subjects excluded from Safety boost set - BNT162b1

Safety set

Dose group	Subject number	Reason for exclusion	Date of first informed consent	Date of screening
10 µg Younger	10010	Subject did not receive two doses of IMP	22APR2020	22APR2020
20 µg Younger	10182	Subject did not receive two doses of IMP	09JUL2020	09JUL2020
50 µg Younger	10050	Subject did not receive two doses of IMP	05MAY2020	05MAY2020
60 µg Younger	10066	Subject did not receive two doses of IMP	08MAY2020	08MAY2020
	10075	Subject did not receive two doses of IMP	11MAY2020	11MAY2020
	10076	Subject did not receive two doses of IMP	11MAY2020	11MAY2020
	10078	Subject did not receive two doses of IMP	11MAY2020	11MAY2020
	10083	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10084	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10085	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10089	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10093	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10096	Subject did not receive two doses of IMP	12MAY2020	12MAY2020
	10103	Subject did not receive two doses of IMP	14MAY2020	14MAY2020
	10104	Subject did not receive two doses of IMP	14MAY2020	14MAY2020
20 µg Older	20242	Subject did not receive two doses of IMP	28AUG2020	28AUG2020

IMP = investigational medicinal product.

Program: Lbase_Disp_4_2.sas (Page 1 of 1)

Listing 16.2.1-4.3-1: Listing of subjects excluded from Immunogenicity set - BNT162b1

Safety set

Dose group	Subject number	Reason for exclusion	Date of first informed consent	Date of screening
30 µg Older	10350	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10351	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10352	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10353	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10358	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10360	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10361	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10362	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10363	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10364	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10365	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020
	10366	Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment	14SEP2020	14SEP2020

IMP = investigational medicinal product.

Program: Lbase_Disp_4_2.sas (Page 1 of 1)

Listing 16.2.1-4.2-3: Listing of subjects excluded from Safety boost set - BNT162b2

Safety set

Dose group	Subject number	Reason for exclusion	Date of first informed consent	Date of screening
1 µg Younger	20160	Subject did not receive two doses of IMP	15JUN2020	15JUN2020
10 µg Younger	20116	Subject did not receive two doses of IMP	20MAY2020	20MAY2020

IMP = investigational medicinal product.

Program: Lbase_Disp_4_2.sas (Page 1 of 1)

Listing 16.2.1-4.3-3: Listing of subjects excluded from Immunogenicity set - BNT162b2

Safety set

No subjects were excluded from Immunogenicity set.